Modality
Multispecific
MOA
CD3xCD20
Target
APOC3
Pathway
Lipid Met
Gastric Ca
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
~Dec 2019
→ ~Mar 2021
Phase 2
Jun 2021
→ Jan 2030
Phase 2Current
NCT04157499
707 pts·Gastric Ca
2021-06→2030-01·Terminated
707 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-01-123.8y awayPh2 Data· Gastric Ca
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P2
Termina…
Catalysts
Ph2 Data
2030-01-12 · 3.8y away
Gastric Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04157499 | Phase 2 | Gastric Ca | Terminated | 707 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 |